Cannara Doubles Down on Curaleaf Deal, Targeting C$34M in International Cannabis Sales
Event summary
- Cannara expanded its supply agreement with Curaleaf, increasing the potential contract value from C$21M to C$34M over two years.
- The deal covers international medical cannabis sales through Curaleaf’s distribution network.
- Cannara’s Valleyfield facility now has 15 of 24 grow rooms active, with remaining capacity for future scaling.
- Curaleaf is supporting Cannara’s pursuit of EU-GMP certification for its processing center.
- Cannara maintains a low-cost production model leveraging Québec’s favorable energy costs.
The big picture
Cannara’s expanded deal with Curaleaf underscores the growing trend of Canadian cannabis producers seeking international medical markets to offset domestic saturation. The partnership leverages Curaleaf’s distribution network, while Cannara’s low-cost production model positions it competitively in a price-sensitive global market. The deal’s scale—C$34M over two years—highlights the strategic importance of international expansion for mid-tier Canadian cannabis firms.
What we're watching
- Execution Risk
- Whether Cannara can sustain production quality and cost discipline while scaling operations.
- Regulatory Dynamics
- The pace at which Cannara achieves EU-GMP certification for its processing center.
- Market Expansion
- How the expanded Curaleaf partnership will impact Cannara’s international sales growth.